Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox, Vitamin D and Azacitidine in High Risk MDS
NCT01718366Phase 2Unknown
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Feb 2013
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of deferasirox in myelodysplastic syndrome (MDS), sponsored by Groupe Français des Myélodysplasies. Status: unknown.
02
Drugs
deferasirox
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01718366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01718366.